By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

RegeneRx Biopharmaceuticals, Inc. 

3 Bethesda Metro Center, Suite 630

Bethesda  Maryland  20814  U.S.A.
Phone: 301-280-1992 Fax: 301-280-1996


SEARCH JOBS








Company News
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Dr. Michael Chopp Reports On Successful Remodeling Of The Central And Peripheral Nervous Systems After Injury/Disease Using Thymosin Beta 4 10/23/2014 11:28:09 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Allowed To Proceed With Phase 3 Using RGN-259 Eye Drops For The Treatment Of Neurotrophic Keratopathy 10/20/2014 8:27:43 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Canadian Patent For Inhibition Or Reversal Of Skin Aging 9/30/2014 9:16:22 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives $1 Million Pursuant To Product License And Stock Purchase Agreement 9/3/2014 12:06:40 PM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: New Report: Thymosin ?4 Prevents Heart Rupture & Improves Cardiac Function After Heart Attack In Mice 7/15/2014 7:32:01 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX)’s Strategic Partner G-Treebnt Preparing For Phase 3 Dry Eye Trials In Asia With RGN-259 7/7/2014 10:16:00 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Release: Chinese FDA Accepts Phase 2 IND For RGN-259 For Dry Eye 6/23/2014 11:45:39 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Issues Letter To Shareholders 5/22/2014 8:04:12 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives $1.35 Million Pursuant To Product License And Stock Purchase Agreement 3/31/2014 8:36:57 AM
RegeneRx Biopharmaceuticals, Inc. (RGRX) And Digital Aria Sign Product License And Stock Purchase Agreements 3/7/2014 8:40:12 AM
12345678910...
//-->